This study is suggesting that a moisturizer containing Kinetin is a good choice for rosacea skin as it is well tolerated and offers some reduction in the redness, lesions and otherwise appearance of rosacea.
Tolerability and efficacy of a moisturizing lotion containing 0.1% kinetin for improving the signs of acne rosacea in facial and neck skin
Jerry McCullough, DPharm, Jashin Wu, MD, University of California, Irvine, Irvine, CA, United States; Greg Kircorian, MD, Valeant Pharmiceuticals, Costa Mesa, CA, United States
Introduction: This study was designed to evaluate the tolerability and efficacy of a moisturizing cream containing 0.1% kinetin (N6-furfuryladenine) for improving the signs and symptoms of acne rosacea and photoaging signs on the face.
Methods: An open-label study with a total of 18 healthy male and female patients (age range: 18-74 years) with mild to moderate acne rosacea is under way. Patients applied 0.1% kinetin moisturizing lotion twice daily to the entire face, once in the morning and again in the evening about 1 hour before bedtime for 12 weeks. A sunscreen was also used during therapy (SPF 30), applied approximately 1 hour after the morning application of 0.1% kinetin lotion. Patients were assessed at baseline, 4, 8, and 12 weeks. Evaluations include physician assessments of inflammatory lesion count, severity of erythema and telangiectasia, photodamage, and skin tolerance and patient assessments of signs and symptoms of rosacea rated on a 4-point scale (0 = none; 1 = mild; 2 = moderate; 3 = severe); Investigator’s Global Assessment (IGA) rated on a 7-point scale (0 = clear, 1 = minimal, 2 = mild, 3 = mild/moderate, 4 = moderate, 5 = moderate/severe, 6 = severe); and Investigator’s Assessment of Overall Improvement rated on a 6-point scale (1 = excellent [100% improvement], 2 = marked [75% improvement], 3 = moderate [50% improvement], 4 = slight [25% improvement], 5 = no improvement, 6 = worse). Patient assessments of tolerability rated on a 4-point scale (1 = good, 2 = acceptable despite minor irritation; 3 = less acceptable due to more problematic irritation, and 4 = unacceptable) In addition, clinical photos were taken.
Results: 18 patients have enrolled in the study of which 8 patients completed 12 weeks of treatment. The mean physician assessment of overall clinical improvement from baseline reported was slight (25% improvement) at week 4 and moderate to slight (50% to 25% improvement) at weeks 8 and 12. The mean patient reported tolerability was good throughout the study therapy. There were no study-related serious adverse events.
Conclusion: Results of this study suggest that 0.1% kinetin lotion may be a well tolerated moisturizing lotion option for patients with mild to moderate acne rosacea and may suggest that 0.1% kinetin lotion has efficacy in reducing the clinical signs of acne rosacea.
Featured Product
Author disclosure: Nothing disclosed at press time. Research supported by an unrestricted research grant provided by Valeant Pharmaceuticals. (Valeant Pharmaceuticals is the manufacturer of the Kinerase range of products).
Poster Discussion Session P599, American Academy of Dermatology, 64th Annual Meeting, March 3-7 2006, San Francisco.
Supplement to Journal of The American Academy of Dermatology, March 2006, Volume 54, Number 3.
Related Articles:
